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Chronic hepatitis B is a major cause of liver-related death worldwide. Interleukin-12 (IL-12) induction
accompanies viral clearance in chronic hepatitis B virus infection. Here, we tested the therapeutic potential of
IL-12 gene therapy in woodchucks chronically infected with woodchuck hepatitis virus (WHV), an infection
that closely resembles chronic hepatitis B. The woodchucks were treated by intrahepatic injection of a
helper-dependent adenoviral vector encoding IL-12 under the control of a liver-specific RU486-responsive
promoter. All woodchucks with viral loads below 1010 viral genomes (vg)/ml showed a marked and sustained
reduction of viremia that was accompanied by a reduction in hepatic WHV DNA, a loss of e antigen and surface
antigen, and improved liver histology. In contrast, none of the woodchucks with higher viremia levels re-
sponded to therapy. The antiviral effect was associated with the induction of T-cell immunity against viral
antigens and a reduction of hepatic expression of Foxp3 in the responsive animals. Studies were performed in
vitro to elucidate the resistance to therapy in highly viremic woodchucks. These studies showed that lympho-
cytes from healthy woodchucks or from animals with low viremia levels produced gamma interferon (IFN-)
upon IL-12 stimulation, while lymphocytes from woodchucks with high viremia failed to upregulate IFN- in
response to IL-12. In conclusion, IL-12-based gene therapy is an efficient approach to treat chronic hepadna-
virus infection in woodchucks with viral loads below 1010 vg/ml. Interestingly, this therapy is able to break
immunological tolerance to viral antigens in chronic WHV carriers.
Hepatitis B virus (HBV) infection is estimated to cause
approximately 1 million deaths per year (http://www.who.int
/emc). Current therapies against chronic HBV include pegy-
lated alpha interferon (IFN-) and nucleoside/nucleotide an-
alogs, such as lamivudine, entecavir, adefovir, and tenofovir
(16). Sustained antiviral responses are achieved in only one-
third of the patients treated with pegylated IFN- (16, 32).
Nucleoside/nucleotide analogs are effective, but treatment
must be continued for many years, resulting in high costs, the
emergence of drug-resistant variants, and frequent relapses
after the discontinuation of therapy (32).
Chronic HBV infection is associated with defects in antiviral
immunity (3). Patients with an acute self-limiting HBV infec-
tion develop neutralizing anti-HBs antibodies and multispe-
cific CD4 and CD8 T-cell responses with a type 1 cytokine
profile (3). In contrast, patients with chronic HBV infection
show no protective humoral immunity and a weak or undetect-
able virus-specific T-cell response (5). The precise mechanism
responsible for this immunotolerance is still unknown. Re-
cently, several studies have indicated that regulatory T cells
(Tregs), immunosuppressive cytokines, and inhibitory recep-
tor-ligand interactions, such as PD1-PDL1, contribute to the
impairment of virus-specific T-cell responses in chronic HBV
infection (1, 17, 23, 26, 28).
Interleukin-12 (IL-12) is a cytokine produced by antigen-
presenting cells that is essential for the induction of effective
cell-mediated immunity against viruses and other pathogens
(30). IL-12 promotes Th1-type responses, enhances cytotoxic-
T-cell activity, and stimulates T lymphocytes and NK cells to
produce IFN- (30). The administration of recombinant IL-12
(rIL-12) to HBV-transgenic mice resulted in the inhibition of
HBV replication in the liver (8). In vitro studies demonstrated
that IL-12 was able to enhance HBV-specific T-cell responses
in chronic HBV carriers (15, 22, 31). Moreover, the upregula-
tion of IL-12 production has been shown to be associated with
HBe seroconversion, indicating an important role for this cy-
tokine in the control of HBV infection (22). In two studies,
rIL-12 administered to patients with chronic HBV infection
once per week as monotherapy (7) or twice weekly in combi-
nation with lamivudine (21) increased virus-specific T-cell re-
activity and exerted significant antiviral activity. However, in
both studies, a rebound of viremia occurred following drug
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withdrawal. The antiviral effects of rIL-12 were dose depen-
dent, but the therapy was limited by severe toxicity when high
doses of the cytokine were used (7, 21).
Gene therapy can significantly increase cytokine expression
in the target organ without excessively elevating systemic cy-
tokine levels, which leads to an increased efficacy/toxicity ratio.
In the present study, we tested the antiviral potential of IL-12-
mediated gene therapy using a high-capacity adenovirus (HC-
Ad) encoding murine IL-12 (mIL-12) under the control of a
liver-specific inducible promoter that is responsive to the pro-
gesterone antagonist RU486 (30). HC-Ad is a nonintegrating
vector characterized by strong hepatotropism, low toxicity,
long-term transgene expression, and high cloning capacity (13).
All these properties make HC-Ad a useful tool for therapeutic
applications in human liver diseases.
As an animal model of chronic HBV infection, we used
woodchucks that were chronically infected with woodchuck
hepatitis virus (WHV). WHV is a hepadnavirus with a genomic
organization, biological properties, and a replicative strategy
that are essentially identical to those of HBV. When WHV
infects woodchucks in the perinatal period of life, the infection
causes chronic hepatitis in most animals. This condition resem-
bles the pathological features and natural history of chronic
hepatitis B (18). Here, we demonstrate that prolonged intra-
hepatic expression of IL-12 overcomes immunological toler-
ance for WHV antigens and induces sustained antiviral effects
in woodchucks with chronic WHV infection and viral loads
below 1010 viral genomes (vg)/ml. These observations indicate
that IL-12 gene therapy is an alternative approach for the
treatment of chronic HBV infection.
MATERIALS AND METHODS
HC-Ads. HC-Ads expressing green fluorescent protein (GFP) under the con-
trol of the cytomegalovirus (CMV) promoter (HC-Ad–CMV–GFP) (14) or
mIL-12 under the control of a liver-specific inducible promoter responsive to
mifepristone (RU486) (HC-Ad/RUmIL-12) were constructed and produced as
described previously (13, 30).
Animals. Adult woodchucks (Marmota monax) chronically infected with WHV
were trapped in the state of Delaware and purchased from North Eastern
Wildlife (Ithaca, NY). The manipulation of animals, including ultrasound-guided
biopsies and virus injection, was performed under general anesthesia. A dose of
2  1010 infectious units (i.u.) of HC-Ad/RUmIL-12 or HC-Ad–CMV–GFP was
injected into the liver following medial laparotomy (9). After laparotomy, the
liver was exposed, the needle was introduced into the liver parenchyma, and the
virus was injected very slowly in a volume of 200 to 500 l, depending on the
purpose of the study. In the first study, which was performed to determine the
transduction efficiency of HC-Ad and the biological activity of mIL-12, the virus
was injected into the major liver lobe (the L3 lobe) in a volume of 500 l. In the
second study, which was performed to test the antiviral potency of the vector, the
virus was injected into three different lobes of the liver in a volume of 200 l per
injection site. IL-12 expression was induced by intraperitoneal administration of
500 g of RU486/kg body weight (30). Blood was obtained from the saphena vein
in isoflurane-anesthetized woodchucks. The study was performed in accordance
with the guidelines of the local ethical commission for animal experiments.
Organ sample processing. After sacrifice or the natural death of the animal,
the liver, lung, spleen, heart, kidney, pancreas, intestine, stomach, muscle, brain,
and ovaries or testes were harvested. The liver was divided into different parts
that we named L1, L2, L3, L4, and L5. Three different samples were obtained
from every organ and liver region, and each sample was processed individually.
Determination of serum and tissue mIL-12 levels. Serum mIL-12 (p70) was
quantified using OptEIA ELISA kits (Pharmingen, San Diego, CA) according to
the manufacturer’s instructions. Frozen tissues were homogenized in cytokine
buffer (50 mM Tris-HCl, pH 7.4, 1% NP-40, 0.25% Na-deoxycholate, 150 mM
NaCl, 1 mM EDTA, and a protease inhibitor cocktail) and centrifuged for 5 min
at 9,300  g. The supernatants were used for cytokine level analysis. The total
protein concentration was determined by using the Bradford assay.
Histological studies. Immunohistochemical staining was performed using the
EnVisionTM System (Dako, Glostrup, Denmark) and rabbit anti-human CD3
epsilon and peroxidise-labeled goat anti-rabbit (Dako) antibodies according to
the manufacturer’s recommendations. The reactions were visualized by incubat-
ing the sections with DAB chromogen (Dako). The stained sections were
counterstained with hematoxylin, dehydrated, and mounted in DPX. Positively
stained cells were enumerated with the motorized Axioplan 2ie microscope. At
least 50 fields were examined, and the number of CD3 cells per 100 hepatocytes
was determined. Liver biopsy specimens were evaluated by experienced liver
pathologists, and histological changes were scored according to the method
developed by Knodell.
Virological assays. PCR primers for the amplification of total DNA (t-DNA)
were designed to detect all forms of WHV DNA, including replication-compe-
tent DNA, intermediate forms (replicative intermediate DNA [RI-DNA]), and
covalent closed circular DNA (cccDNA) (Table 1). Serum WHV DNA was
isolated using a High Pure Viral Nucleic Acid Kit (Roche Diagnostics, Lewes,
United Kingdom) and was quantified by real-time quantitative PCR (qPCR).
The detection limit of the assay was 10 vg per l of serum (2). t-DNA and the
cccDNA-enriched fraction were extracted from the liver as previously described
(33). For the extraction of intracellular viral DNAs, liver biopsy samples were
disrupted in 1.5 ml of 0.01 M Tris-HCl (pH 7.5) and 0.01 M EDTA. Half of the
homogenate was used for the extraction of RI-DNA, and half was used for
cccDNA preparation. For the extraction of RI-DNA, the homogenate was ad-
justed to a total volume of 6 ml with 0.025 M Tris-HCl (pH 7.4), 0.01 M EDTA,
0.25% (wt/vol) sodium dodecyl sulfate, 0.05 M NaCl, and pronase (2 mg/ml).
After a 1-h incubation at 37°C, nucleic acids were extracted with a 1:1 mixture of
phenol-chloroform and collected by ethanol precipitation. For cccDNA extrac-
tion, the volume of the remainder of the homogenate was adjusted to 3 ml with
0.01 M Tris-HCl (pH 7.5) and 0.01 M EDTA; 200 l of 10% (wt/vol) sodium
TABLE 1. Nucleotide sequences of primers and probes used in the present study to quantify DNA or mRNA of target sequences by qPCR
Target
sequencea Probe
Primer
Sense Antisense
WHV (core Ag) 5-AGAAGATCTCAATCACCGCGTCGCA-3 5-AGAAGACGCACTCCCTCTCCT-3 5-TGGCAGATGGAGATTGAGAGC-3
HBV 5-AGAAGATCTCAATCACCGCGTCGCA-3 5-AGAAGACGCACTCCCTCTCCT-3 5-TGGCAGATGGAGATTGAGAGC-3
IRES (rIL-12) 5-CCCGGAAACCTGGCCCTGTCTT-3 5-GCCGTCTTTTGGCAATGTG-3 5-CCCCTAGGAATGCTCGTCAA-3
wIFN- 5-TCACTGCTTTACGCTGGATCTTCAGGT
CA-3
5-TCCTAAAGGTGTCTCAAGTTCAGG
A-3
5-CTTAGGGTAGAGTGTGGTAACA
GATCAT-3
wTGF- 5-CTGGCTCTGTACAACCA-3 5-GGACACGCAGTACAGCAAGGT-3 5-GATGCGCCTGGGTTGTG-3
w-actin 5-TGCGTGACATCAAGAGAAG-3 5-TCACCCACACTGTGCCCATCTACGA-3 5-CAGCGGAACCGCTCATTGCCAAT
GG-3
wFoxP3 NAb 5-CAGCACATTCCCAGAGTTCCTC-3 5-GCGTGTGAACCAGTGGTAGAT
C-3
wCD4 NA 5-TGAAGAACCAGGCGGCTAAG-3 5-AACATTGGCTGGTACTGGTT-3
WHVcccDNA 5-AATGGGAGGAGGGCAGCATTGAT-3 5-GGTCCGTGTTGCTTGGTC-3 5-TGGAACACAGGCAAAAACAA-3
WHV t-DNA 5-TCCTGCTGCTGTGCCTCATCTT-3 5-GAGTGCACTTGGCCAAAATTC-3 5-GCATTGTTCTGCAATTGACTGT-3
a IRES, internal ribosome entry site; w, woodchuck.
b NA, not applicable.
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dodecyl sulfate was then added, the mixture was briefly vortexed, and 1 ml of 2.5
M KCl was added. The mixture was incubated at room temperature for 20 min,
and potassium dodecyl sulfate-protein complexes were then collected by centrif-
ugation at 10,000 rpm for 20 min at 4°C. The supernatant was subjected to
phenol-chloroform extraction, and the DNA was precipitated with ethanol over-
night at room temperature (33).
WHV DNA was analyzed by Southern blotting as previously described. WHV
RI-DNA, cccDNA, and woodchuck -actin copy numbers were quantified by
qPCR. Primers and probes are shown in Table 1. The cccDNA primers were
designed using an approach verified for HBV by others (25). The sense primer
(1701 to 1918) is located upstream of the DR2 sequence, within the single-
stranded region of WHV genomic DNA. The antisense primer is located down-
stream of the DR1 sequence (1972 to 1953), and the probe corresponds to the
1846-to-1868 sequence. The numbers denote the position of the sequence in the
WHV genome according to GenBank accession number AY628100. Using these
primers, no amplification product could be obtained from WHV genomic DNA.
To confirm the specificity of the PCR assay for cccDNA, the PCR product was
sequenced after being cloned into the Topo-TA system (data not shown). In
addition, the cccDNA quantification was repeated after digestion with Plasmid-
Safe ATP-dependent DNase, an enzyme that digests linear double-stranded
DNA, as well as linear and closed single-stranded DNAs, but not closed double-
stranded circular DNA (data not shown). The plasmid DNA construct pWHV8
containing a monomer of the WHV8 genome, provided by M. Roggendorf, was
used as a positive control. This plasmid was also used as a standard to determine
total WHV-DNA and cccDNA copy numbers. A good linear range was observed
from 102 to 109 copies of plasmid in real time with both sets of primers (data not
shown). The lowest detectable cccDNA copy number was assigned as the limit of
detection of the assay.
The presence of serum WHV surface antigen (WHsAg) levels was determined
by enzyme-linked immunosorbent assay (ELISA) (2, 19). The WHV e antigen
(WHeAg) concentration was determined using a commercial ELISA for HBVe
antigen that recognizes woodchuck antigen (DiaSorin S.p.A., Saluggia, Italy).
Anti-WHV specific cellular immunity. The T-cell proliferative response to
WHcAg stimulation was analyzed using freshly isolated peripheral blood mono-
nuclear cells (PBMCs) as previously described (2). Briefly, freshly isolated
PBMCs were cultured in 96-well U-bottom plates at a density of 2  105
cells/well in complete RPMI medium. WHcAg was added in triplicate at a final
concentration of 1 g/ml. Forty-eight hours later, the supernatants were har-
vested and the IL-2 concentration was determined using a CTL-L2 assay (2).
Stimulation index (SI) values of 3.1 were considered positive for a specific
PBMC response.
Activation of woodchuck PBLs with plate-bound anti-CD3 antibody. Wood-
chuck peripheral blood lymphocytes (PBLs) were stimulated with immobilized
anti-human, anti-mouse, and anti-rat CD3 (clones UCHT1, 145-2C11, and
G4.18, respectively; BD Biosciences) at a concentration of 2 g/ml. Only the
anti-rat CD3 antibody was able to induce IFN- production from woodchuck
PBLs (data not shown; I. Otano, J. Prieto, S. Henne, and G. G. Aseguinolaza,
unpublished data). The analysis of the proliferation induced by plate-bound
anti-rat CD3 was performed using a flow cytometric assay with 5- and 6-carboxy-
fluorescein diacetate succinimidyl ester (CFSE) (Molecular Probes), as de-
scribed elsewhere, with minor modifications (12). Briefly, woodchuck PBMCs
were labeled with 5 mM of CFSE and were activated with plate-bound anti-CD3
antibody at a concentration of 2 g/ml. The plates were incubated for 3 days. The
cells were harvested and analyzed on a FACSCalibur flow cytometer (Becton
Dickinson). The lymphocyte population was gated, and the diluted CFSE fluo-
rescence in dividing cells was determined using Flow Jo software (Becton Dick-
inson). The SI was defined by the percentage of dividing cells.
Purification and analysis of woodchuck regulatory T cells. To purify wood-
chuck regulatory T cells, we first tested antibodies against CD25 that were
developed from different species. Only anti-human CD25 antibody (clone M-
A251) recognized a subpopulation of T lymphocytes in woodchuck PBMCs
(Otano et al., unpublished). CD25-expressing T cells were purified from wood-
chuck PBMCs by magnetic separation according to the manufacturer’s instruc-
tions (MACS isolation system; Miltenyi Biotec). After purification, FoxP3 ex-
pression was analyzed with a FACSCalibur flow cytometer (Becton Dickinson).
CD25 and CD25 cells were stained with anti-CD25–allophycocyanin and then
fixed and permeabilized according to the manufacturer’s instructions (e-Bio-
sciences). Phycoerythrin-conjugated anti-mouse/rat FoxP3 antibody (clone FJK-
16S; e-Biosciences) was added for 20 min at 4°C. The cells were washed twice and
analyzed by flow cytometry.
Analysis of woodchuck regulatory T-cell activity. CFSE-labeled PBMCs were
activated with plate-bound -CD3 in triplicate in the presence or absence of
CD25 purified T cells at a ratio of 10:1. Three days later, the proliferation of
PBMCs was monitored by fluorescence-activated cell sorter, and the SI was
determined.
Analysis of the immunostimulatory activity of mIL-12. Freshly isolated
PBMCs were cultured in 96-well U-bottom plates at a density of 1  105
cells/well in complete RPMI medium. rmIL-12 was added in triplicate at a
concentration of 1 ng/ml. Forty-eight hours later, the cells were harvested and
RNA was extracted. Woodchuck IFN- and -actin mRNA levels were quanti-
fied using reverse transcription (RT)-qPCR, as described below.
Analysis of mRNA expression by qPCR. Total RNA was extracted using Trizol,
and the total RNA (2 g) was treated with DNase (Gibco-BRL, Paisley, United
Kingdom) prior to RT with Moloney murine leukemia virus reverse transcriptase
(Gibco-BRL) in the presence of RNaseOut (Gibco-BRL). Transgenic mIL-12
(internal ribosome entry site sequence), woodchuck IFN-, woodchuck trans-
forming growth factor  (TGF-), WHV pregenomic RNA (pgRNA), and wood-
chuck -actin were measured by real-time qPCR using a LightCycler (Roche
Diagnostic, Mannheim, Germany), primers, and Taqman probes (Applied Bio-
systems). Woodchuck CD4 and Foxp3 expression levels were measured using a
LightCycler or a TaqMan ABI Prism 7000 instrument (Applied Biosystems) with
the LC-DNA Master SYBR green mix. Primers and probes were designed using
Primer-Express software (Table 1). The number of copies of mIL-12, woodchuck
IFN-, woodchuck TGF-, WHV pgRNA, and woodchuck -actin were deter-
mined by interpolation using external DNA standards. Woodchuck CD4 and
Foxp3 final amplification products were analyzed by using melting curves. The
relation between the two transcripts was expressed by the following formula:
2	CT(CD4)  CT(Foxp3), with CT being the threshold cycle, the point at which the
fluorescence rises significantly above background.
Biochemistry. Alanine aminotransferase (ALT), aspartate aminotransferase
(AST), bilirubin, and lactate dehydrogenase (LDH) levels were determined by
using a Boehringer Mannheim Hitachi (Mannheim, Germany) 911 automatic
analyzer. In our laboratory, the normal range for these biochemical markers in
woodchucks chronically infected with WHV are as follows: ALT, 0 to 20 IU/liter;
AST, 0 to 40 IU/liter; bilirubin, 0.10 
 0.05 mg/dl; and LDH, 400 to 700 IU/liter.
Hematology analysis. Whole blood was collected in EDTA-containing tubes,
and complete blood counts were determined using a semiautomatic electronic
blood cell counter (Sysmex F-800). Normal blood cell counts found in wood-
chucks chronically infected with WHV in our institution are as follows: platelets,
500  109 to 800  109/liter; leukocytes, 13  109 to 16  109/liter; lymphocytes,
4  109 to 8  109/liter; and neutrophils, 5.5  109 to 9  109/liter.
Statistical analysis. All statistical calculations were performed with SPSS 11.0
software (SPSS Inc., Chicago, IL). To establish significance between woodchuck
groups, statistical analysis was performed using the Kruskal-Wallis test followed
by a comparison of the control group with the experimental groups that used the
Mann-Whitney test with Bonferroni’s correction. The liver biopsy data was
evaluated by the Knodell score and was placed in a contingency table for com-
parison with a Somer’s D test. Hepatic expression of Foxp3 between woodchuck
groups was compared using Student’s t test after logarithmic transformation of
the data.
Nucleotide sequence accession number. The Woodchuck Foxp3 cDNA se-
quence GenBank accession number is EU168437.
RESULTS
RU486 administration induced IFN- expression and lym-
phocyte infiltration in the livers of animals treated with HC-
Ad/RUmIL-12. The homologies of the woodchuck IL-12 p35
and IL-12 p40 proteins to the corresponding known subunits of
the murine forms of these molecules were 49% and 63%,
respectively. In vitro tests showed that mIL-12 was active on
woodchuck PBMCs by efficiently inducing IFN- mRNA ex-
pression in these cells (Fig. 1). In addition, preliminary exper-
iments were performed to study the biodistribution of HC-Ad/
RUmIL-12 and the vector’s ability to transduce the woodchuck
liver and to induce IL-12 expression following RU486 admin-
istration. Two woodchucks with chronic WHV infection and
viral loads of 2.52  1010 vg/ml (woodchuck no. 350) and
1.19  1011 vg/ml (woodchuck no. 813) received a single dose
of 2  1010 i.u. of HC-Ad/RUmIL-12 by direct intrahepatic
injection into the largest liver lobe (9). Two weeks later, trans-
gene expression was induced for 5 days by daily intraperitoneal
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administration of 500 g of RU486/kg body weight. Ten hours
after the first and fifth dose of RU486, blood samples were
obtained to determine mIL-12 levels in serum by ELISA. As
shown in Fig. 2A, RU486 induced a significant rise in serum
mIL-12 levels in both animals. Following the last dose of
RU486 on day 5, the woodchucks were sacrificed for analysis of
mIL-12 levels in different organs. The presence of mIL-12 was
detected by ELISA in different areas of the liver, but it was also
found in the kidney (Fig. 2B). The IL-12 concentration was
highest in the area surrounding the injection site (L3), fol-
lowed by the neighboring liver regions (L2 and L4) (Fig. 2B).
mIL-12 mRNA was also detected in L3, as well as in the other
liver lobes, but was found only at very low levels in other
organs, such as the spleen, lung, heart, and kidney (Fig. 2C).
The analysis of virus biodistribution in these animals was per-
formed by qPCR and showed that the virus was mainly detected
in the liver (1.3  104 
 0.25  104 and 1.1  104 
 0.32  104
vg of HC-Ad/RUmIL-12 per 106 woodchuck -actin copies
were detected in woodchuck no. 350 and woodchuck no. 813,
respectively) and at very low levels in the spleen, lung, heart,
and kidney (data not shown). This indicated that no significant
leakage of virus occurred after intrahepatic injection, as we
had previously described for mice (9).
Because IFN- is induced by IL-12, the expression of this
cytokine in different tissues was also determined. The highest
values for IFN- mRNA were seen in the injected liver lobe,
but increased mRNA expression was also detected to a lesser
extent in other organs (Fig. 2D). Hematoxilin-eosin staining
(Fig. 2E) and anti-CD3 immunohistochemistry in liver biopsies
(Fig. 2F) performed before and after mIL-12 induction re-
vealed lymphocytic infiltration not only in the injected lobe,
but also in other areas of the liver (data not shown).
Prolonged induction of IL-12 in the liver exerts antiviral
effects that are dependent on the pretreatment viral load. In
order to test whether prolonged expression of mIL-12 within
the woodchuck liver could produce an antiviral effect on
chronic WHV infection, eight woodchucks with chronic WHV
infection and stable viremia levels over at least 2 months were
treated with a single dose of 2  1010 i.u. of HC-Ad/RUmIL-
12. The virus was administered at laparotomy by intrahepatic
injection in three different liver areas. Two weeks after vector
injection, mIL-12 expression was induced for 42 days by daily
intraperitoneal administration of 500 g of RU486/kg body
weight. Two control groups were included in the study; one
group (n  2) received a single dose of 2  1010 i.u. of
HC-Ad–CMV–GFP intrahepatically, and the second group (n 
3) received only intraperitoneal injections of RU486 daily for
42 days.
Serum samples were obtained before vector injection and
then every 2 weeks during the induction period and follow-up
(for 200 days after the injection of the vector). Liver biopsy
specimens were obtained at days 14, 35, and 130. One wood-
chuck in the treatment group died after being biopsied on day
35 because of intestinal perforation (woodchuck no. 796), and
a second woodchuck died on day 90 because of pneumonia
(woodchuck no. 622). The organs from these animals were still
harvested and used for analysis.
In woodchucks treated with HC-Ad/RUmIL-12 plus RU486,
a reduction in the viral load of no greater than 2 log units was
determined to be a lack of response to the therapy. Remark-
ably, all animals with basal viremia levels below 1010 vg/ml
exhibited an intense and sustained decrease of serum WHV
DNA from pretreatment levels upon IL-12 induction (Fig.
3A). In contrast, mIL-12 induction did not produce compara-
ble effects on WHV replication in woodchucks with pretreat-
ment viremia levels above 1010 vg/ml (Fig. 3B). None of the
woodchucks included from the control groups showed changes
in viremia during the study period (Fig. 3C).
Following RU486 administration, mIL-12 expression levels
in serum varied widely among animals but were comparable
between the two groups. Further, mIL-12 concentrations be-
came undetectable by the end of the RU486 administration
period (Fig. 3D and E). No detectable mIL-12 was present in
the sera of control animals during the study (data not shown).
Enough liver tissue could be harvested from all the treated
woodchucks except for one animal (woodchuck no. 156) for
WHV DNA determination by Southern blotting. A marked
reduction of WHV DNA in the liver was found in responder
woodchucks no. 796, no. 173, and no. 622, whereas wood-
chucks from the high-viremia group showed no changes in the
levels of hepatic WHV DNA (Fig. 4A and B). Levels of WHV
t-DNA and cccDNA in the liver were determined by qPCR on
t-DNA- and cccDNA-enriched fractions, respectively, and
were normalized using -actin copy numbers (33). As shown in
Fig. 3A and B, the percentages of the initial levels of t-DNA
and cccDNA remaining at the end of treatment were closely
correlated with the decrease in viremia. Moreover, analysis of
WHV pgRNA by RT-qPCR following RNA extraction from
liver tissue and normalization to -actin mRNA levels demon-
strated a marked reduction of this transcript in woodchucks
with low viremia levels, whereas comparable reductions were
not observed in woodchucks with high viremia levels (Fig. 4C).
Correlating with these results, woodchucks from the re-
sponder group that were WHeAg and WHsAg positive prior
to the treatment cleared WHeAg and WHsAg levels in the
serum during the IL-12 induction period or shortly thereaf-
ter. Animals that failed to respond to the treatment re-
mained positive for WHeAg and WHsAg throughout the
study (Fig. 4D and E).
FIG. 1. Analysis of the immunostimulatory activity of mIL-12 in
woodchuck PBMCs. Freshly isolated PBMCs from non-WHV-infected
woodchucks were cultured in 96-well U-bottom plates at a density of
1  105 cells/well in complete RPMI medium. rmIL-12 was added in
triplicate at different concentrations: 0, 0.01, 0.1, 1, 10, and 100 ng/ml.
Forty-eight hours later, cells were harvested, RNA was extracted, and
woodchuck IFN- and woodchuck -actin mRNA levels were esti-
mated by RT-qPCR. The means and standard deviations are indicated.
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FIG. 2. Liver transduction by HC-Ad/RUmIL-12 in WHV-infected woodchucks and analysis of IL-12’s immunostimulatory activity. Two
woodchucks with chronic WHV infection received HC-Ad/RUmIL-12 by injection into the major liver lobe (L3). Two weeks later, mIL-12 was
induced for five consecutive days. (A) Serum mIL-12 levels were measured by ELISA before induction (day 0) and at days 1 and 5 following RU486
administration. (B) The woodchucks were sacrificed 10 h after the last RU486 administration, and different organs were dissected from the two
animals as detailed in Materials and Methods. Three samples from each organ were obtained, and each sample was processed individually. Tissue
homogenates were prepared from different liver lobules (L1, L2, L3, L4, and L5) and various organs (S, spleen; Lu, lung; H, heart; K, kidney).The
mIL-12 concentration was determined by ELISA, and the total protein concentration was determined using the Bradford assay. Samples in both
assays were evaluated in triplicate. The values represent the means 
 standard deviations (SD) of the data obtained from the three samples of
each tissue from woodchucks no. 350 (w350) and 813 (w813). (C and D) Total RNA was extracted from the different samples, and the levels of
mIL-12 (C), woodchuck IFN- (D), and woodchuck (w) -actin transcripts were quantified by RT-qPCR in triplicate. The values represent the
means 
 SD of the data obtained from the three samples of each tissue from the two woodchucks. IRES, internal ribosome entry site. (E and F)
Liver sections were stained with hematoxylin-eosin (E) or for CD3 (F) before treatment and after mIL-12 induction. The numbers of CD3-positive
T cells per 100 hepatocytes 
 SD are shown.
VOL. 83, 2009 IMMUNOGENE THERAPY FOR CHRONIC VIRAL HEPATITIS 2667
 o
n
 August 29, 2012 by Universidad de Navarra
http://jvi.asm.org/
D
ow
nloaded from
 
IL-12 treatment reduces liver inflammation in responder
animals. Liver biopsy samples from treated woodchucks were
analyzed in a blinded manner by an experienced pathologist.
The responder group showed an improvement in the Knodell
score (P value  0.063), while nonresponding animals with
high viremia did not (Fig. 5).
Intrahepatic expression of IL-12 activates the antiviral im-
mune response. The T-cell response to WHcAg was tested
monthly by measuring the production of woodchuck IL-2 from
PBMCs stimulated with WHcAg (2). None of the animals
showed an antigen-specific T-cell response prior to treatment
(Fig. 6A and B). Following induction of mIL-12 expression, all
woodchucks with low viremia developed a positive T-cell re-
sponse to WHcAg either during the mIL-12 induction period
or shortly thereafter. Importantly, this development of a T-cell
response paralleled the drop in viremia levels. In contrast, only
one of the woodchucks from the high-viremia group gave a
positive T-cell response to WHV core antigen after the IL-12
induction period (Fig. 6B).
Characterization of woodchuck regulatory T cells. Antiviral
T-cell responses are inhibited by poorly understood mecha-
nisms in chronic HBV carriers. Tregs have been shown to be
expanded in chronic HBV carriers and can inhibit specific
antiviral T-cell responses (26, 27). In mice, the transcription
factor Foxp3 is a key marker for regulatory T cells (10). How-
ever, in humans, Foxp3 can also be expressed by activated CD4
and CD8 T cells (23). Thus, we tested whether woodchuck T
cells expressing FoxP3 have regulatory activity. For this pur-
pose, we purified CD25 cells from woodchuck PBMCs by
magnetic separation. As shown in Fig. 7A, 60% of woodchuck
CD25 cells expressed Foxp3. Furthermore, after -CD3 stim-
ulation, the Foxp3-enriched T-cell fraction produced TGF-,
but not IFN-, while PBMCs expressed both cytokines (Fig.
6B). Next, we analyzed the regulatory activity of the Foxp3-
enriched T-cell fraction. For this purpose, CFSE-labeled
CD25 cells were stimulated with plate-bound -CD3 in the
presence or in the absence of CD25 cells. As shown in Fig. 7C
and D, the presence of CD25 cells inhibits the proliferation
of -CD3-stimulated CD25 cells.
Intrahepatic expression of IL-12 was associated with a re-
duction of Foxp3 levels in the livers of the chronic WHV
carriers that responded to therapy. After confirming the reg-
ulatory activity of the Foxp3-enriched T-cell fraction, we an-
alyzed the expression of Foxp3 in the livers of 10 healthy
woodchucks, 10 woodchucks with chronic WHV infection, and
5 woodchucks that had resolved acute WHV infection between
3 and 5 years before the study. Foxp3 values were significantly
increased in woodchucks with chronic WHV infection com-
pared to uninfected woodchucks and compared to animals that
cleared the virus after acute infection (Fig. 7E). We observed
a tendency for hepatic Foxp3 values to decrease during the
IL-12 induction period with respect to pretreatment levels in
FIG. 3. Liver IL-12 expression inhibits viral replication in animals with basal viremia levels below 1010 vg/ml. (A and B) Eight woodchucks
(individual numbers are shown preceded by “w”) with chronic WHV infection received an intrahepatic injection of HC-Ad/RUmIL-12 (2  1010
i.u. per animal) into three different regions of the liver. Two weeks later, mIL-12 was induced for 42 consecutive days by intraperitoneal
administration of RU486 at 500 g/kg body weight. WHV DNA was measured by qPCR in serum every 2 weeks starting 50 days before virus
injection and during the 200 days after injection. The animals were divided into two groups: the responder group (A), in which the reduction of
the viral load was greater than 2 log units, and the nonresponder group (C). (C) The effects on viremia were also determined in five woodchucks
with chronic WHV infection (basal viral load, 1010 vg/ml) that were used as controls: two (GFP) received 2  1010 i.u. of the control vector
HC-Ad–CMV–GFP (a gutless vector expressing GFP), and three (RU) received only intraperitoneal administration of RU486 at 500 g/kg body
weight. (D and E) Serum mIL-12 was serially determined in both groups of woodchucks before and after virus injection, during the induction
period, and after cessation of RU486 administration.
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all animals subjected to IL-12 gene therapy. Interestingly,
Foxp3 expression continued to decrease after the discontinu-
ation of IL-12 induction in woodchucks that responded to
treatment, while there was a marked increase of Foxp3 expres-
sion in animals that failed to respond to therapy (Fig. 7F).
In vitro responsiveness of PBMCs to rIL-12 depends upon
the viral load. Most of the immunostimulatory effects of IL-12
are mediated by IFN- (29). Thus, to further characterize the
mechanisms underlying the lack of a response to mIL-12 in
woodchucks with high viremia, we tested the effect of this
cytokine on IFN- induction in PBMCs from healthy and
WHV-infected woodchucks. PBMCs obtained from healthy
woodchucks (n  3), woodchucks with viremia levels below
1010 vg/ml (n  3), and woodchucks with viremia levels above
1010 vg/ml (n  6) were incubated with mIL-12 at a concen-
tration of 1 ng/ml. After 24 h, the cells were harvested, total
RNA was extracted, and IFN- expression was analyzed by
RT-qPCR. Interestingly, we found that while IFN- was clearly
induced upon mIL-12 stimulation in PBMCs from healthy
woodchucks or from woodchucks with viral loads below 1010
vg/ml, there was no IFN- response to mIL-12 in animals with
viremia levels above 1010 vg/ml (Fig. 8). These data reveal that
the blockade of IFN- induction may be an important factor
in the resistance to IL-12-based therapy.
Toxicity of HC-Ad/RUmIL-12-based therapy. To evaluate
the possible toxicity associated with mIL-12 induction, blood
samples from woodchucks treated with HC-Ad/RUmIL-12
were obtained weekly between days 24 and 100 of the study.
Slight increases of serum bilirubin, transaminases, and LDH
shortly after vector injection were observed, followed by a
FIG. 4. A decrease in circulating WHV DNA was correlated with the reduction in virological parameters in the liver and other viral markers
in serum. t-DNA- and ccc-DNA-enriched fractions were prepared from liver biopsy specimens obtained 14 days before vector injection and 130
days after virus injection. DNA was extracted from the liver necropsy samples in the two woodchucks that died during the treatment. WHV DNA
was analyzed by Southern blotting and by qPCR using primers specific for the WHV core sequence. cccDNA copy numbers were determined by
qPCR as described in Materials and Methods. (A) Data for the responder woodchucks (individual numbers are shown preceded by “w”). (B) Data
for the nonresponder woodchucks. t-DNA and cccDNA baseline levels were arbitrarily considered as 100%. RNA was extracted from liver biopsy
specimens or necropsy samples. (C) WHV pgRNA levels in the liver were determined by RT-qPCR specific for the WHV core sequence. (D and
E) The levels of WHsAg (D) and WHeAg (E) in serum were determined by ELISA in responder woodchucks (continuous lines) and nonresponder
woodchucks (dotted lines). OD, optical density.
FIG. 5. Responder animals showed improvement in liver histology.
The Knodell scores of histological changes in the liver biopsy speci-
mens obtained at pretreatment and at the end of the study or death of
the animal are shown. For statistical analysis, the data were plotted in
a contingency table and then compared by using Somer’s D test. The
error bars indicate standard errors.
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second peak in transaminase and LDH levels after the end of
the IL-12 induction period (Fig. 9A and B). All parameters
returned to normal values by day 100. In addition to the
changes in liver enzymes, we also observed a moderate in-
crease of platelets and leukocytes (both neutrophils and lym-
phocytes) during the mIL-12 induction period; these values
returned to pretreatment levels by day 100 (Fig. 9C and D).
Changes in serum transaminases, bilirubin, LDH, and blood
cell counts were similar in both responders and nonresponders
to therapy.
DISCUSSION
Ideally, a therapy for chronic HBV infection would activate
antiviral immunity in order to promote seroconversion and
induce efficient and long-lasting control of viral replication. In
vitro, IL-12 has been reported to restore the hyporesponsive-
ness of T cells to viral antigens from patients with chronic
hepatitis B (15, 22, 31). It has also been shown that an increase
of IL-12 precedes seroconversion to anti-HBe, and therapy
with rIL-12 can reduce the viral load in chronic HBV infection
(7, 21, 22). However, the use of rIL-12 is limited by IFN--
mediated toxicity when IL-12 is given intravenously (7, 21).
The induction of IL-12 expression within the liver is an
attractive therapeutic strategy because it makes it possible to
achieve higher concentrations of the cytokine in the diseased
organ rather than in the systemic circulation, thus increasing
the therapeutic window (30). In order to transduce liver cells,
we employed HC-Ad because these vectors allow long-term
transgene expression, have low toxicity, and posses a high clon-
ing capacity that permits the introduction of regulatory se-
quences to control transgene expression (13). We used mIL-12
as a transgene, since this murine cytokine induced IFN- ex-
pression in woodchuck lymphocytes similarly to woodchuck
IL-12, and it has the advantage that it can be detected and
quantified using commercial tools (data not shown). In our
study, intrahepatic administration of HC-AdRU/mIL-12 was
well tolerated and allowed higher levels of both IL-12 and
IFN- to be expressed in the liver than in other organs. In
previous work, we showed that intrahepatic injection of adeno-
viral vectors caused fewer inflammatory reactions than the
intravascular route of injection. This is likely because a higher
proportion of the vector dose gains direct access to hepato-
cytes, thus avoiding Kupffer cell filtering (9).
The present work demonstrates that liver-directed mIL-12-
based gene therapy in chronic WHV infection induces a
marked antiviral effect in the group of animals with pretreat-
ment viremia levels below 1010 vg/ml, but not in animals with
viremia levels above 1010 vg/ml. The difference in the efficacy
of the treatment between the two groups of woodchucks did
not depend on the level of transgene expression because the
serum mIL-12 concentrations were similar for both groups,
although individual variation was noticed (20). Despite the
induction of antiviral effects, the serum mIL-12 levels were
almost undetectable in some of the treated animals. Thus,
intrahepatic mIL-12 expression levels do not parallel circulat-
ing levels of the cytokine. In fact, in the two animals depicted
in Fig. 1 (woodchucks no. 350 and 813), which were sacrificed
during the induction of mIL-12, we observed considerable dif-
ferences in serum mIL-12 levels while the intrahepatic IL-12
concentrations were similar in the two animals. These findings
are reminiscent of observations in patients with renal carci-
noma who were treated with rIL-12 (20). In these patients,
high variability in serum IL-12 concentrations was detected
among subjects receiving similar doses of the cytokine. It was
suggested that this variability might be related to individual
variation in the expression of IL-12 receptor. This might also
explain the variability of serum IL-12 levels in woodchucks that
received similar doses of vector and inducer. This hypothesis
should be tested in further studies.
Importantly, woodchucks that responded to the therapy and
were WHeAg and WHsAg positive prior to IL-12 induction
cleared both antigens from the serum and developed specific
T-cell responses against WHcAg. In contrast, WHeAg and
WHsAg levels persisted in the sera of all nonresponder ani-
mals, and a WHcAg-specific antiviral T-cell response was ob-
served in only one woodchuck from this group. These findings
indicate that IL-12 gene transfer to the liver is a therapeutic
strategy that is capable of breaking the immunotolerance to
viral antigens that develops in animals infected during the
neonatal period of life.
FIG. 6. Expression of IL-12 in the liver can break immunotolerance against viral antigens. Animals that responded to the treatment (A) and
nonresponders (B) (individual numbers are shown preceded by “w”) were tested for T-cell responses against WHcAg during the study period.
PBMCs were isolated before and at different time points during and after treatment. The PBMCs were cultured in a 96-well plate at a density of
2  105 cells/well, and rWHcAg was added in triplicate at a concentration of 1 g/ml. Forty-eight hours later, the supernatants were harvested and
the IL-2 concentration was determined using a CTL-L2 assay (2). SI values of3.1 were considered positive for a specific PBMC response. †, death
of the animal.
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The relationship between the antiviral effect of IL-12 gene
therapy and the level of viremia is in agreement with observa-
tions in patients with chronic hepatitis B. Boni et al. have
demonstrated that in HBV-infected patients with low viremia,
the reservoir of CD8 cells present in the peripheral circula-
tion was able to expand after specific virus recognition,
whereas such expansion did not occur in highly viremic pa-
tients (4, 6). Similar data have emerged from other studies
showing that woodchucks with chronic WHV infection were
able to mount a strong antigen-specific immune response fol-
FIG. 7. Analysis of woodchuck Treg activity and liver Foxp3 expression. CD25 cells were purified from woodchuck PBMCs by magnetic
separation. (A) CD25 and CD25 cells were labeled with anti-CD25–allophycocyanin and anti-Foxp3–phycoerythrin and analyzed by flow
cytometry. Representative flow cytometry profiles are shown. (B) CD25 cells or total PBMCs were activated with plate-bound anti-CD3, and
TGF- and IFN- expression levels were analyzed by RT-qPCR. The means and standard deviations are indicated. (C) CFSE-labeled PBMCs were
activated with plate-bound anti-CD3 in triplicate in the presence or in the absence of CD25 cells at a ratio of 10:1. Three days later, the
proliferation of PBMCs was monitored by flow cytometry and the SI was determined. A representative flow cytometry profile is indicated in the
figure. SSC-H, side-light scatter. (D) SIs were determined for five different woodchucks (individual numbers are shown preceded by “w”) under
the experimental conditions described for panel C. (E) Foxp3 mRNA levels in the livers of healthy woodchucks, woodchucks with chronic WHV
infection, and woodchucks that eliminated the virus after resolution of acute WHV infection. (F) Foxp3 mRNA in the livers of responder and
nonresponder animals treated with HC-Ad/RUmIL-12 plus RU486.
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lowing vaccination only after prolonged viremia reduction with
potent antiviral drugs given for several months (19).
Interestingly, we found that PBMCs from woodchucks with
high viremia levels showed an impairment in the induction of
IFN- following stimulation with IL-12, while this alteration
was not observed in animals with low viremia levels. Although
the molecular mechanisms responsible for this defect clearly
deserve further investigation, it must be noted that this alter-
ation has also been detected in patients with chronic hepatitis
B. The presence of large amounts of HBV DNA in serum is
associated with suppressed costimulatory effects of IL-12 on
HBV-induced immune responses (24). The elucidation of the
mechanism responsible for the IL-12 unresponsiveness will be
of great value for the development of more efficient therapies
based on the gene delivery of immunostimulatory cytokines.
Recently, chronic HBV infection has been shown to be as-
sociated with an expansion of Tregs in the peripheral blood (7,
26, 27). This cell population mediates peripheral immunotol-
erance and can inhibit specific antiviral immune responses to
HBV (26). Here, we have shown in woodchucks that the
FIG. 8. Activation of woodchuck PBMCs by rmIL-12. Freshly isolated PBMCs from healthy woodchucks (n  3) and from woodchucks with
low (n  3) and high (n  5) viremia were incubated with or without mIL-12 (1 ng/ml) for 48 h in triplicate. Then, woodchuck IFN- and -actin
mRNA levels were quantified by RT-qPCR. The mean values of triplicates are indicated. The analysis was repeated at least three times with similar
results.
FIG. 9. Biochemical and hematology data from HC-Ad/RUmIL-12-treated animals. AST, ALT, LDH, and bilirubin were measured before and
after HC-Ad/RUmIL-12 injection and during and after IL-12 induction. (A) We observed a small increase in serum transaminases after virus
injection and during the IL-12 expression period. These levels returned to normal after cessation of IL-12 expression. (B) Bilirubin elevation was
observed after virus injection and during the IL-12 induction period, while LDH increased only after virus injection. (C and D) Platelet (C) and
leukocyte, lymphocyte, and neutrophil (D) numbers were measured in all woodchucks treated with HC-Ad/RUmIL-12 plus RU486. Day zero is
the day of HC-Ad/RUmIL-12 injection. IL-12 expression induction was initiated at day 14 during 42 days as described in the text. The error bars
represent standard deviations. V.i., virus injection; Ind., Induction.
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Foxp3-enriched T-cell fraction has immunosuppressive func-
tions, produces large amounts of TGF-, and inhibits the pro-
liferation of anti-CD3 activated T cells (Fig. 5B to D). Fur-
thermore, as previously described in humans, we demonstrated
that chronic WHV infection is characterized by high levels of
Foxp3 expression in the liver (Fig. 5E). Interestingly, we ob-
served a tendency for Foxp3 values to decrease during the
induction of IL-12 in all animals. After interruption of the
therapy, hepatic Foxp3 expression almost disappeared in re-
sponder animals, while Foxp3 was markedly upregulated in
nonresponder woodchucks. This result suggests a reexpansion
of Tregs in the liver in this group of animals. Our data do not
allow us to discriminate whether the decrease of Foxp3 expres-
sion observed in the livers of responder woodchucks is merely
a consequence of the reduction in viral load or is due to a
specific effect of IL-12 on the Treg population.
The antiviral effect mediated by IL-12 gene therapy was
associated with only a modest elevation of liver enzymes, in-
dicating that the control of WHV infection is mainly carried
out by a noncytolytic, cytokine-mediated mechanism, as previ-
ously demonstrated in HBV-transgenic mice and HBV-in-
fected chimpanzees (11). Such a mechanism appears to be
capable of reducing or eliminating viremia and clearing WHV
from the livers of the responder animals. Interestingly, we
observed an improvement of liver histology in those animals
that showed a positive antiviral response to therapy.
Chronic WHV infection is associated with a greater viral
load than chronic HBV infection. In chronic hepatitis B, pa-
tients with high viremia have HBV DNA concentrations that
range between 107 and 108 vg/ml. It is noteworthy that all
woodchucks with viremia in this range responded to the liver-
directed IL-12-based gene therapy as measured by the activa-
tion of antiviral immune responses, efficient control of viral
replication, and improved liver histology. Because this treat-
ment strategy was effective and safe in chronic WHV infection,
it deserves consideration as a potential therapy for patients
with chronic HBV infection, especially in patients who have a
low viral load or who are undergoing prolonged treatment with
nucleoside/nucleotide analogs.
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